Guaifenesin/hydrocodone - Sovereign Pharmaceuticals

Drug Profile

Guaifenesin/hydrocodone - Sovereign Pharmaceuticals

Alternative Names: Guaifenesin/hydrocodone bitartrate oral solution; Guaifenesin/hydrocodone tartrate oral solution; Hydrocodone bitartrate/guaifenesin oral solution; Hydrocodone tartrate/guaifenesin oral solution; Obredon

Latest Information Update: 20 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sovereign Pharmaceuticals
  • Class Antitussives; Expectorants; Morphinans; Opioid analgesics; Opioid peptides; Propylene glycols; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Cough

Most Recent Events

  • 06 Jan 2015 Launched for Cough in USA (PO) before January 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top